Filing Flows › 4D Molecular Therapeutics (FDMT) › Who owns the stock
Who owns 4D Molecular Therapeutics (FDMT) stock
146 funds reported 4D Molecular Therapeutics (FDMT) shares in their latest 13F filings, worth $837M in all. The largest holder is Jupiter Topco LLC ($76.5M). Last quarter 83 funds added to their stakes and 53 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Jupiter Topco LLC | 5,746,289 | $76.5M | base | 2026-06-30 |
| RA Capital Management, L.P. | 5,049,779 | $67.2M | unchanged | 2026-06-30 |
| BlackRock | 4,546,059 | $60.5M | increase | 2026-06-30 |
| Goldman Sachs Group | 4,258,668 | $56.6M | increase | 2026-06-30 |
| Janus Henderson Group | 5,247,151 | $48.9M | increase | 2026-03-31 |
| Novo Holdings A/S | 3,249,178 | $43.2M | decrease | 2026-06-30 |
| State Street | 2,911,109 | $38.7M | increase | 2026-06-30 |
| BVF | 2,879,289 | $38.3M | unchanged | 2026-06-30 |
| T. Rowe Price Investment Management | 2,511,887 | $33.4M | new | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 2,249,203 | $29.9M | increase | 2026-06-30 |
| Trails Edge Capital Partners, LP | 2,227,917 | $29.6M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 2,099,055 | $27.9M | decrease | 2026-06-30 |
| Armistice Capital, LLC | 2,000,000 | $26.6M | unchanged | 2026-06-30 |
| Vanguard Group | 3,093,527 | $23.2M | increase | 2025-12-31 |
| Geode Capital Management, LLC | 1,128,466 | $15.0M | increase | 2026-06-30 |
4D Molecular Therapeutics' latest quarter
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most FDMT stock?
By the latest 13F filings: Jupiter Topco LLC ($76.5M); RA Capital Management, L.P. ($67.2M); BlackRock ($60.5M); Goldman Sachs Group ($56.6M); Janus Henderson Group ($48.9M).
What is the short interest in FDMT?
11,530,134 shares were sold short at the 2026-10-15 settlement, 2.59% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.